Tests vancomycin's effect on gut bacteria and immunity in multiple sclerosis
Tests vancomycin against placebo in adults with multiple sclerosis, examining gut bacteria.
Plain-language title generated from the registry record
Registry title: Vancomycin Study in Multiple Sclerosis (MS)
Key facts
- Where
- New York, United StatesSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Source: NCT05539729, who can take part
Where in United States
- Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount SinaiNew York, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Icahn School of Medicine at Mount Sinai
- Trial code
- NCT05539729
- Record updated
- 28 September 2026
- Original description
The overall goal of this study is to elucidate a mechanism by which vancomycin modulates the gut-brain axis in multiple sclerosis (MS). The gut microbiome plays an important role in autoimmunity, including MS. However, the identity of gut microbes modulating neuroinflammation in MS and their mechanisms of action remain obscure. Hence, here the research team proposes to investigate the effects of vancomycin on the gut microbiota composition, peripheral immune function, and brain MRI lesions in MS patients.Read full original descriptionShow less
Impact of Vancomycin on the Gut Microbiome and Immune Function in Multiple Sclerosis
The overall goal of this study is to elucidate a mechanism by which vancomycin modulates the gut-brain axis in multiple sclerosis (MS). The gut microbiome plays an important role in autoimmunity, including MS. However, the identity of gut microbes modulating neuroinflammation in MS and their mechanisms of action remain obscure. Hence, here the research team proposes to investigate the effects of vancomycin on the gut microbiota composition, peripheral immune function, and brain MRI lesions in MS patients.
Inclusion: aged 18 - 50; newly diagnosed MS (2017 McDonald criteria), CIS or RIS patients, who have experienced symptoms no earlier than the past year; treatment naive; able to understand the risks, benefits, and alternatives of participation and give meaningful consent.
Exclusion: pre- or probiotic use within past month or corticosteroids use within the past month; history of treatment with immunosuppressants; history of gastroenteritis within the past month or diagnosis with a chronic infectious disease, i.e. hepatitis B, C or HIV; irritable bowel syndrome and other bowel dysfunction such as constipation; history of bowel surgery; inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, diabetes and any other auto-immune illness; diagnosis with another neurological disease, behavioral or psychiatric conditions that would be incompatible with a safe and successful participation in the study (such as severe major depression, schizophrenia and presence of psychotic symptoms); eating disorders such as anorexia nervosa, bulimia, or binge eating syndrome; contraindication to vancomycin including estimated glomerular filtration rate of <60ml/min, impaired hearing or known allergy; antibiotic use within the past 90 days; use of tobacco products within the past 1 month; pregnancy or less than 6 months postpartum; travel outside of the country within the past month; Contraindication to MRI such as implanted metallic objects.